Clinical trials
Castrate Sensitive Prostate Cancer clinical trials
Below are recruiting castrate sensitive prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 95 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07717268RecruitingPhase 2
Stereotactic Radiation Plus New Hormone Therapy for Prostate Cancer
This trial tests a targeted, high-dose radiation therapy (SBRT) plus a newer hormone drug (abiraterone or enzalutamide) for men whose prostate cancer has spread to a small number of spots (5 or fewer) and is no longer controlled by standard hormone therapy.
Zaragoza, AragonAges Any age - NCT06039371RecruitingPhase 2
High dose testosterone during chemo for advanced prostate cancer
This trial tests if adding high doses of testosterone to standard chemotherapy (etoposide and carboplatin) can make the chemo work better in men whose prostate cancer has stopped responding to other treatments. It aims to see if this approach can shrink tumors or slow cancer growth.
Seattle, WashingtonAges 18 years+ - NCT06378866RecruitingPhase 2
Radiation with hormone therapy timing for prostate cancer
This study is testing whether using focused radiation beams (SBRT) right away or later, along with hormone therapy, can help control prostate cancer that has returned in a few spots outside the pelvis. The goal is to find the best timing for combining radiation and hormone treatment.
Phoenix, ArizonaAges 18 years+ - NCT03787056Recruiting
Blood test marker study in many cancer types
This study measures a blood marker called progastrin (at diagnosis and during treatment) to see how well it predicts response or outcomes. It may help doctors choose or monitor treatment more precisely for several cancer types.
BronAges 18 years+ - NCT03819101RecruitingPhase 3
Aspirin plus atorvastatin for advanced, treatment-resistant prostate cancer
This trial studies whether daily aspirin and atorvastatin can slow advanced prostate cancer that has continued to grow despite hormone therapy. It may help by reducing cancer growth and inflammation, but you would need to meet several specific safety and medication rules.
OlomoucAges 18 years+ - NCT03833921RecruitingPhase 2
Testing abiraterone and prednisone for metastatic prostate cancer by race
This trial studies how well abiraterone (a hormone-blocking medicine) plus prednisone (a steroid) works in people with metastatic, hormone-sensitive prostate cancer. It also looks at whether results differ by race/ethnicity and other health factors.
Houston, TexasAges 18 years+ - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Anchorage, AlaskaAges 18 years+ - NCT04221542RecruitingPhase 1
AMG 509 for advanced, hormone-resistant prostate cancer
This trial tests AMG 509, a study drug, in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite lowering testosterone). It’s for people whose cancer has progressed after certain hormone tablets and possibly chemotherapy, aiming to shrink tumors and control the disease safely.
Duarte, CaliforniaAges 18 years+ - NCT04633252RecruitingPhase 1/Phase 2
Study drug plus docetaxel and abiraterone for advanced prostate cancer
This trial tests a new targeted cancer drug (PDS01ADC) combined with standard treatments docetaxel and abiraterone for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and whether it can control cancer better than current approaches.
Bethesda, MarylandAges 18–110 - NCT04729114RecruitingPhase 1
Safety and dose test of PRL-02 shot for advanced prostate cancer
This Phase 1 study tests how safe PRL-02 depot (an injection) is and finds the best dose for men with advanced prostate cancer. It may help determine a new treatment option for cancers that have spread or are getting worse despite standard care.
Tucson, ArizonaAges 18 years+ - NCT04734730RecruitingPhase 2
Talazoparib plus hormone therapy for metastatic prostate cancer
This trial tests whether talazoparib added to standard hormone therapy (ADT), along with abiraterone, can better control metastatic prostate cancer that hasn’t progressed despite starting hormone treatment. It may help people live longer and delay cancer worsening.
Duarte, CaliforniaAges 18 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after abiraterone
This trial tests whether a drug called talazoparib, alone or combined with enzalutamide, can help people with a certain type of advanced prostate cancer that has stopped responding to abiraterone. It is for those who have a specific genetic change (HRR mutation) in their tumor.
Duarte, CaliforniaAges 18 years+ - NCT04946370RecruitingPhase 1/Phase 2
Pembrolizumab plus prostate cancer drug, with or without radiation
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
Boston, MassachusettsAges 18 years+ - NCT05168618RecruitingPhase 2
Cabozantinib and atezolizumab for advanced prostate cancer
This Phase 2 trial tests cabozantinib plus atezolizumab in people with metastatic prostate cancer that keeps growing despite hormone-blocking therapy and newer hormone drugs. It may help shrink tumors and control the disease, especially in advanced cases where options are limited.
Salt Lake City, UtahAges 18 years+ - NCT05352178RecruitingPhase 3
Targeted treatment for few-spread prostate cancer spots
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
LeuvenAges 18 years+ - NCT05422911RecruitingPhase 2
Abiraterone, enzalutamide, or apalutamide for early castration prostate cancer
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
Los Angeles, CaliforniaAges 18 years+ - NCT05720130RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer found on PSMA scans
This trial tests [212Pb]Pb-ADVC001, a radiotherapy-like cancer treatment, in people with advanced prostate cancer that shows up on a special PSMA scan. It aims to find the safest dose and see whether it helps shrink or control metastatic cancer.
Brisbane, QueenslandAges 18 years+ - NCT05869682RecruitingPhase 2
Bright light therapy for fatigue and depression in prostate cancer
This Phase 2 study tests whether a “bright white light” intervention can reduce cancer-related fatigue and depression in people with advanced prostate cancer receiving hormone-based treatment. If it works, it could improve day-to-day well-being while you’re on standard cancer therapies.
Duarte, CaliforniaAges 60 years+ - NCT06190899RecruitingPhase 1/Phase 2
Testing gedatolisib plus darolutamide in advanced prostate cancer
This trial tests a new combination of two drugs, gedatolisib and darolutamide, in men with prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the combination can help control the cancer when standard treatments have stopped working.
Detroit, MichiganAges 18 years+ - NCT06200103RecruitingPhase 2
Can we pause 177Lu-PSMA-617 therapy after a good response?
This trial tests whether it's safe to pause 177Lu-PSMA-617 therapy in men whose prostate cancer has responded very well to it. Doctors want to see if taking a break from treatment can reduce side effects without letting the cancer come back.
Rochester, MinnesotaAges 18 years+ - NCT06236789Recruiting
Ifosfamide for men with advanced prostate cancer
This trial is studying whether the chemotherapy drug ifosfamide (given with mesna to protect the bladder) can help men whose prostate cancer has spread and is no longer controlled by hormone therapy. It is for men who have already tried the chemotherapy docetaxel.
SeoulAges 19 years+ - NCT06244004RecruitingPhase 2
PET-guided radiation for metastatic hormone-sensitive prostate cancer
This trial tests whether using a special PET scan (FDG-PET) to find and treat only the spots where cancer has spread with targeted radiation can help men with prostate cancer that has spread but still responds to hormone therapy. It compares standard treatment alone to standard treatment plus this targeted radiation.
Chicago, IllinoisAges 18 years+ - NCT06353386RecruitingPhase 1/Phase 2
Opevesostat combinations for advanced prostate cancer
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06392295RecruitingPhase 2
PSMA-Guided Radiation for Limited Prostate Cancer Return
This trial tests whether targeted radiation to the lymph nodes in the belly can help men whose prostate cancer has returned in just a few spots after prior radiation. You must have had a PSMA PET/CT scan showing the cancer is limited to pelvic or belly lymph nodes.
Miami, FloridaAges 18 years+
Hear when a new Castrate Sensitive Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for castrate sensitive prostate cancer?
- Yes. Clin2 currently lists 95 recruiting castrate sensitive prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a castrate sensitive prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a castrate sensitive prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Castrate Resistant Prostate Cancer
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Castration Sensitive Prostate Cancer
- Hormone Sensitive Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Prostate Cancer (Adenocarcinoma)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.